参考文献 [1] Camidge DR, Kim HR, Ahn MJ,et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 1;38...
Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial [published online ahead...
For example, the phase 3 ALTA-1L trial showed that brigatinib may have improved Overall Survival (OS) compared to crizotinib if treatment switching had not occurred. Their sensitivity analysis using Inverse Probability of Censoring Weights (IPCW), reported a Hazard Ratio (HR) of 0.50 (95% CI...
and the ALTA-1L trial demonstrates that brigatinib has the potential to be a key player in the first-line setting,” said D. Ross Camidge, MD, PhD, Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center and the lead investigator of ALTA-1L. “The ALTA...
Camidge DR et al: Inhibitor–naive ALK-positive non–small cell lung cancer: Second interim analysis of the phase III ALTA-1 L trial. J Clin Oncol 38 (31), 2020, 3592-3603. Table 2. Time to Worsening in EORTC QLQ-C30 Scores Among PRO-ITT Population. ScoresMedian Time to Worsening,...
1. Myung-Ju Ahn,et al. Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial. Presented at ASCO Annual Meeting; 2019 May 31-June4; Chicago. Abstract #9026. 2. Rosario Garcia Campelo, et al. Health-related quality of life...
Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial - ScienceDirectBackground In the first preplanned interim analysis (IA) from ALTA-1L (NCT02737501; median follow-up BRG/CRZ: 11.0/9.3 mo, 99 PFS events), ...
Safety results were consistent with the known profile for brigatinib, with no new safety findings.Clinical trial information: NCT02737501;NCT03410108.American Society of Clinical OncologyJournal of Clinical Oncology
In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim ...
Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trialdoi:10.1016/S0169-5002(20)30164-1R. CalifanoD. CamidgeH.-R. KimM.-J. AhnS. PopatElsevier BVLung Cancer